Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital.

Slides:



Advertisements
Similar presentations
Methods for Studies in Preventing Cognitive Loss and Dementia
Advertisements

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Department of Neurology, Mayo Clinic Arizona
Alzheimer’s Disease Edwin Onattu P. 3.
Frontotemporal Dementia
AD Research Update Steven H. Ferris, PhD Friedman Professor and Director NYU Alzheimer’s Disease Center Silberstein Alzheimer’s Institute Center for Cognitive.
BERG SYMPOSIUM WASHINGTON UNIVERSITY SEPT 2003 MICHAEL W WEINER MD.
Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.
Healthy Mind, Healthy Sight.. u Dr. Guy Eakin, BrightFocus Foundation u Dr. Elia Duh, Johns Hopkins University u Dr. Seth Margolis, Johns Hopkins University.
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
Gender Difference in Alzheimer’s Disease Neuropathology EH Corder, E Ghebremedhin, M Taylor, DR Thal, TG Ohm, H Braak Dr. Senckenbergische Anatomie Department.
AGING AND TRAUMA Key Points Increased longevity results in increased neurological disorders ‘Normal’ age-related changes in brain structure Neurodegenerative.
FTD Family Members Study & Post Mortem Study Alyson Negreira MGH Frontotemporal Disorders Unit.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND.
Decision presented by the committee board members: Nicholas Mann & Katelyn Strasser FUTURE FUNDING FOR ALZHEIMER’S DISEASE October 14, 2014 MPH 543 Leadership.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
ALZHEIMER’S PART 2. AD VIDEO
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
Alzheimer’s Disease Landscape
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
ALZHEIMER PATHOLOGY AND NEUROPLASTICITY AD ATTACKS NEUROPLASTIC MECHANISMS NEUROPLASTICITY AS THE FOCUS OF THE ALZHEMIER ATTACK ALZHEIMER ATTACK AS A MODEL.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Introduction Alzheimer’s is a disease that affects the brain. About 4 million people in the United States have it. It is predicted that 1 in 85 people.
Grow Your Brain at Any Age Majid Fotuhi, MD PhD Howard County Office on Aging Columbia, MD March 28, 2014.
Six Steps to a Better Brain Majid Fotuhi, MD PhD March 6, 2014.
The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.
Alzheimer’s Disease By: Chelcy Branon. Facts  In 2006, there were 26.6 million sufferers worldwide  Costs 100 billion dollars per year.
Medical University of Sofia, Faculty of Medicine Department of Pharmacology and Toxicology Alzheimer’s Disease Avi Gandhi (2009)
Heather Kellogg March 6, 2013 Honors Psychology, Period 1
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
Progressive, degenerative disorder Attacks the brain's neurons Results in loss of memory, thinking and language skills, and behavioral changes Confusion.
Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.
Do you remember what you ate for dinner two days ago?
What is Alzheimer’s Disease?. Neurons and Neurotransmitters Neurons are cells inside the brains. Chemical transmitters (neurotransmitters) which transport.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
Is It Alzheimer’s? The Latest Update on Optimal Evaluation and Treatment of Patients with Memory Loss Majid Fotuhi, MD PhD March 5, 2014.
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
Assessment and Diagnosis of Dementia Dr Alison Haddow.
Epidemiology of Alzheimer’s Disease
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
Recent advances in Trace Element Research in Health and Disease Dubrovnik, Oct 2015 Mirjana Babić Leko, mag.biol.mol Department of Neuroscience Croatian.
Alzheimer’s Disease Today and Tomorrow First case reported in 1906 Reported by Alois Alzheimer Patient Augusta D. first treated at 46 years old Paranoia,
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
Alzheimer's disease 蕭尚益 丁唯洋 蔡欣容. Outline introductionDisease mechanismPreventConclusion.
Can we treat Alzheimers 20 years early? 郭丕鈺 王家豪 張琮貿.
Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.
We Treat Alzheimers 20 years early? Can. Clinical neurologist-Reisa Sperling 1. Is a clinical neurologist, a neuroimaging researcher. 2.Is a leading force.
Alzheimer’s Disease Lizzy Butler & Efe Osemeha. Background Info Alzheimer’s Disease is a neurological disease that kill neurons causing the loss of memory.
The clinical research of early diagnosis and ultimately the treatment of Alzheimer’s disease 許一仁 董冠廷 詹鎮遠 陳柏廷.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.
Alzheimer’s Disease (AD)
Reflections on animal models of neurological disorders Marie-Francoise Chesselet UCLA
Applications of Nanotechnology in Alzheimer’s Disease BioE 494 – Atomic and Molecular Nanotechnology Fall 2007 Deivya Bansal.
AFTD Education Conference Research Update: Focus on Two Large Federally Funded Projects: LEFFTDS and ARTFL David Knopman MD Neurology Mayo Clinic Rochester.
Massachusetts General Hospital
Can We Treat Alzheimers 20 years early?
Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;
Alzheimer’s Disease Group 廖元祺 楊熙恆
What will it take to develop an effective Alzheimer’s drug?
Seizures in Alzheimer’s disease
Imaging AD Progression Amyloid Imaging Agents.
Modifying Disease Course in Alzheimer's Disease
New Therapies in Alzheimer's Disease
Q: How can we prevent or treat Alzheimer’s Disease?
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Patient 2- Alzheimer’s Disease
Natives CARE Understanding Alzheimer's Disease and Dementia in American Indian and Alaska Native People Outreach Clinic Presentation Meghan Jernigan, MPH.
Natives CARE Understanding Alzheimer's Disease and Dementia in American Indian and Alaska Native People Outreach Clinic Presentation Meghan Jernigan, MPH.
Presentation transcript:

Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital

HABS turns 5 and the Mass ADRC turns 30! One of the three oldest Centers of Excellence in the country – our data combined with other Centers leads to >10,000 individuals actively enrolled in studies

What have we learned? What causes age related memory problems or neurodegenerative diseases? – Genes! Alzgene.org 20 new genetic risk factors – many discovered at MGH – Risk factors! Alzrisk.org Primary studies and reviews of the day to day factors that might impact your chance of having memory problems or dementia – Natural history and early changes New definition of the disease from neuropathological studies and new imaging studies – mainly from the ADRC.

What were important questions 25 years ago? Why do patients have memory problems as they age? Why do some people get AD, and others don’t? What goes wrong in the AD brain? How can we treat or prevent AD?

The lesions and genes affecting the Alzheimer Brain Tau tangles form Amyloid plaques form Neurons die Inherited genes predispose

Natural history Clinical diagnosis Ingelsson et al New understanding of disease led to new definitions from international working groups led in part by Drs Hyman, Sperling, Frosch and Blacker in 2012 and 2013

18F T807 SUVR y/o MCI MMSE = 28 PiB (mcDVR) = SUVR AT8 Histochemistry T807 binding represents tangles Braak 2006 Keith Johnson, 2014

Early diagnosis and new therapies Early changes in amyloid, tau, and behaviors such as the sense of smell precede and to some extent anticipate cognitive deterioration. Early diagnosis – even presymptomatic diagnosis – might lead to a window where we can intervene. The A4 trial – led by Dr Sperling and Rentz

New projects pushing the frontiers of science Can we see the loss of neurons with a new generation of MRI scanner? - Dr Trey Hedden Why are some people resilient to disease? - Dr Teresa Gomez Isla Can we create better animal models of disease? Dr Brad Hyman

It’s a great partnership! Thank you!!!!!